Treatment of liver metastases from colorectal cancer: what is the best approach today?

被引：19

作者：

Biasco, G ^{[1
]}

Gallerani, E ^{[1
]}

机构：

[1] Univ Bologna, Osped S Orsola Malpighi, Inst Hematol & Med Oncol L&A Seragnoli, I-40138 Bologna, Italy

来源：

DIGESTIVE AND LIVER DISEASE | 2001年 / 33卷 / 05期

关键词：

colorectal cancer; liver metastases; local chemotherapy; systemic chemotherapy;

D O I：

10.1016/S1590-8658(01)80018-9

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Liver is the common site for metastases from colorectal cancer The 5-year overall survival rate of patients following radical operations is 25%. Surgery can be carried out in only 10-15% of the patients, yet it remains the potential curative treatment for resectable lesions. For the unresectable cancers, only chemotherapy is recommended. New drugs such as Irinotecan prolongs the overall survival of patients affected by advanced disease. In patients with unresectable metastases at diagnosis, pre-surgical treatment with Oxaliplatin leads to reduction of the lesions, allowing resection in 16% of cases. Chemotherapy may be delivered directly into the liver via the hepatic artery. No, clinical trials, to date, have shown convincing survival results in patients treated with this procedure. Combined hepatic artery and systemic treatment may provide a new strategy as adjuvant therapy for patients undergoing resections.

引用

收藏

页码：438 / 444

页数：7

相关论文

共 34 条

[1] Portal triad clamping or hepatic vascular exclusion for major liver resection - A controlled study [J].

Belghiti, J ;

Noun, R ;

Zante, E ;

Ballet, T ;

Sauvanet, A .

ANNALS OF SURGERY, 1996, 224 (02) :155-161

[2] Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy [J].

Bismuth, H ;

Adam, R ;

Levi, F ;

Farabos, C ;

Waechter, F ;

Castaing, D ;

Majno, P ;

Engerran, L .

ANNALS OF SURGERY, 1996, 224 (04) :509-520

[3]

Bleiberg H, 1998, SEMIN ONCOL, V25, P32

[4]

Buyse M, 1996, J NATL CANCER I, V88, P252

[5]

CADY B, 1991, SEMIN ONCOL, V18, P399

[6] PHASE-I TRIAL OF 5-DAY CONTINUOUS VENOUS INFUSION OF OXALIPLATIN AT CIRCADIAN RHYTHM-MODULATED RATE COMPARED WITH CONSTANT RATE [J].

CAUSSANEL, JP ;

LEVI, F ;

BRIENZA, S ;

MISSET, JL ;

ITZHAKI, M ;

ADAM, R ;

MILANO, G ;

HECQUET, B ;

MATHE, G .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (12) :1046-1050

[7] Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [J].

Cunningham, D ;

Pyrhönen, S ;

James, RD ;

Punt, CJA ;

Hickish, TF ;

Heikkila, R ;

Johannesen, TB ;

Starkhammar, H ;

Topham, CA ;

Awad, L ;

Jacques, C ;

Herait, P .

LANCET, 1998, 352 (9138) :1413-1418

[8] Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies - Results in 123 patients [J].

Curley, SA ;

Izzo, F ;

Delrio, P ;

Ellis, LM ;

Granchi, J ;

Vallone, P ;

Fiore, F ;

Pignata, S ;

Daniele, B ;

Cremona, F .

ANNALS OF SURGERY, 1999, 230 (01) :1-8

[9] Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study [J].

deGramont, A ;

Basset, JF ;

Milan, C ;

Rougier, P ;

Bouche, O ;

Etienne, PL ;

Morvan, F ;

Louvet, C ;

Guillot, C ;

Francois, E ;

Bedenne, L .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :808-815

[10] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

← 1 2 3 4 →